World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
84
Citations
30994
World Ranking
14958
National Ranking
7558

Overview

Anthony D. Elias is affiliated with the University of Colorado Boulder in the United States. Their research spans multiple areas within medicine and biological sciences, with a significant focus on oncology and related subfields.

The scientist's work primarily covers the following fields of study:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Within these broader categories, their subfields of study include:

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research
  • Radiology, Nuclear Medicine and Imaging
  • Molecular Biology

Elias's research topics concentrate heavily on cancer, particularly breast cancer. Main topics of work comprise:

  • Advanced Breast Cancer Therapies
  • Breast Cancer Treatment Studies
  • Cancer Genomics and Diagnostics
  • HER2/EGFR in Cancer Research
  • Cancer Treatment and Pharmacology
  • Cancer Immunotherapy and Biomarkers
  • Estrogen and related hormone effects

The scientist has contributed to high-impact research venues with frequent publications in:

  • Cancer Research (21 publications)
  • Journal of Clinical Oncology (19 publications)
  • Journal of the National Comprehensive Cancer Network (6 publications)
  • Clinical Cancer Research (5 publications)
  • npj Breast Cancer (5 publications)

Among recent papers authored or co-authored by Anthony D. Elias are:

  • Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology, 2020, Journal of the National Comprehensive Cancer Network
  • Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology, 2022, Journal of the National Comprehensive Cancer Network
  • Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer, 2020, JAMA Oncology
  • NCCN Guidelines® Insights: Breast Cancer, Version 4.2023, 2023, Journal of the National Comprehensive Cancer Network
  • NCCN Guidelines® Insights: Breast Cancer, Version 4.2021, 2021, Journal of the National Comprehensive Cancer Network

Frequent collaborators in their research include:

  • Hope S. Rugo
  • Laura J. Esserman
  • Erica Stringer-Reasor
  • W. Fraser Symmans
  • Douglas Yee

Best Publications

  • Clinical practice guidelines in oncology

    William J. Gradishar;Benjamin O. Anderson;Ron Balassanian;Sarah L. Blair

  • Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

    William J. Gradishar;Benjamin O. Anderson;Jame Abraham;Rebecca Aft

  • Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial

    George D. Demetri;Margaret von Mehren;Robin L. Jones;Martee L. Hensley

  • Effect of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor on Chemotherapy-Induced Myelosuppression

    Karen S. Antman;James D. Griffin;Anthony Elias;Mark A. Socinski

  • GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR EXPANDS THE CIRCULATING HAEMOPOIETIC PROGENITOR CELL COMPARTMENT IN MAN

    MarkA. Socinski;Anthony Elias;Lowell Schnipper;StephenA. Cannistra

  • Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas

    Robert G. Maki;David R. D'Adamo;Mary L. Keohan;Michael Saulle

  • Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

    William D Tap;William D Tap;Robin L Jones;Robin L Jones;Brian A Van Tine;Bartosz Chmielowski

  • Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

    Harold J. Burstein;Anthony D. Elias;Hope S. Rugo;Melody A. Cobleigh

  • An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.

    K Antman;J Crowley;S P Balcerzak;S E Rivkin

  • Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial

    Rita Nanda;Minetta C Liu;Christina Yau;Rebecca Shatsky

  • Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer

    Hope S. Rugo;Olufunmilayo I. Olopade;Angela DeMichele;Christina Yau

  • A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy.

    K Antman;L Ayash;A Elias;C Wheeler

  • NCCN Guidelines® insights breast cancer, version 1.2017: Featured updates to the NCCN Guidelines

    William J. Gradishar;Benjamin O. Anderson;Ron Balassanian;Sarah L. Blair

  • Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome.

    Paul G Richardson;Carol Murakami;Zhezhen Jin;Diane L Warren

  • Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide.

    Dawn R Cochrane;Sebastián Bernales;Britta M Jacobsen;Diana M Cittelly

  • Adaptive Randomization of Neratinib in Early Breast Cancer

    John W Park;Minetta C Liu;Douglas Yee;Christina Yau

  • Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer.

    AD Elias;L Ayash;KC Anderson;M Hunt

  • Invasive breast cancer version 1.2016

    William J. Gradishar;Benjamin O. Anderson;Ron Balassanian;Sarah L. Blair

  • Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy.

    Anthony Elias;Louise Ryan;Aaron Sulkes;Jerry Collins

  • Treatment of Severe Veno-Occlusive Disease With Defibrotide: Compassionate Use Results in Response Without Significant Toxicity in a High-Risk Population

    Paul G. Richardson;Anthony D. Elias;Amrita Krishnan;Catherine Wheeler

Frequent Co-Authors

Karen H. Antman
Karen H. Antman Boston University
Virginia F. Borges
Virginia F. Borges University of Colorado Boulder
Jennifer K. Richer
Jennifer K. Richer University of Colorado Anschutz Medical Campus
Donald A. Berry
Donald A. Berry The University of Texas MD Anderson Cancer Center
Judy C. Boughey
Judy C. Boughey Mayo Clinic
Laura J. Esserman
Laura J. Esserman University of California, San Francisco
Kathy S. Albain
Kathy S. Albain Loyola University Chicago
Hope S. Rugo
Hope S. Rugo University of California, San Francisco
Claudine Isaacs
Claudine Isaacs Georgetown University
Angela DeMichele
Angela DeMichele University of Pennsylvania

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in Medicine opens doors to a wide range of advanced degrees and trajectories beyond the MD. For those interested in healthcare leadership, pursuing one of the top cahme-accredited mha programs can lead to roles in hospital management and administration. These online programs offer flexibility for working professionals who want to move into leadership positions.

Nurses seeking to advance their education may benefit from online rn to bsn programs without clinical requirements, which allow for degree completion without the need for on-site clinical hours. This is particularly appealing for working RNs balancing job commitments and family life.

For those striving to reach the highest levels of nursing practice, there are options such as short dnp programs that enable quicker completion, as well as a variety of dnp online programs designed for convenience and flexibility. These pathways can help medical professionals expand their scope of practice and pursue specialized or leadership positions in healthcare.

Best Scientists Citing Anthony D. Elias

Trending Scientists

Recently Published Articles